NovaBay Pharmaceuticals is an advanced clinical-stage biotechnology company engaged in developing two distinct categories of product offerings. The company’s aim is to address the significant unmet therapeutic needs of the worldwide anti-infective market. The company’s first-in-class Aganocide compounds are patented synthetic molecules that mimic white blood cells to fight against bacteria, viruses, and fungi. NovaBay’s NeutroPhase class of molecule is being developed for advanced wound care. For more information visit the company’s Web site at www.novabaypharma.com

ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com

Let us hear your thoughts below: